Advance in the Diagnosis, Treatment and Prognosis of Hepatocellular Carcinoma
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Gastroenterology & Hepatology".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 14147
Special Issue Editor
Interests: gut microbiota; nutrition; liver disease; probiotic; dyspepsia
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hepatocellular carcinoma (HCC) is the third leading cause of death worldwide, and its incidence is expected to rise significantly in the coming years because of the Westernization taking place around the world. In fact, the growing impact of metabolic disease has reshaped the feature of hepatology. Metabolic-associated fatty liver disease (MAFLD) has become the leading cause of liver cirrhosis and hepatocellular carcinoma. The latter can occur also in the absence of cirrhotic evolution of hepatic disease.
Thus, early HCC diagnosis is a must for clinical and bench research. Over anti-angiogenetic treatment, HCC prognosis and life expectancy are improved by the use of check-point inhibitors. However, the lack of a genetic mutation fingerprint of HCC requires newer biomarkers for more personalized medicine. In this context, the growing role of gut microbiota dysbiosis in liver disease and in HCC physiopathology can be an efficacious tool in the diagnostic and therapeutic armamentarium.
This Special Issue calls for contributions on:
- HCC prevalence and incidence;
- HCC pathophysiology;
- Updates on HCC diagnosis;
- The role of gut microbiota and its dysbiosis in HCC natural history;
- Updates on HCC treatments;
- Special focus on gut microbiota modulation in HCC treatment.
Dr. Emdio Scarpellini
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
-
hepatocellular carcinoma
- metabolic-associated fatty liver disease
- hepatic disease
